-57%

est. 2Y upside i

HealthcareSeries A

Natural functional ingredients that actually work

Rank

#3354

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Exercise high caution.

Last updated: July 19, 2026

Bull (20%)+44%

Revenue hits $10.4M with multiple expanding to 20x due to breakout customer wins and an IPO window. After 20% dilution and preference, common shares gain ~44%.

Base (50%)-73%

Multiple compresses to 6x in line with public comps. Exit of $62.5M after preference leaves common with ~$272k per $1M initial stake, a 73% loss.

Bear (30%)-99%

Multiple drops to 3x. Exit of $31.3M barely covers preference; common recovers nearly nothing, effectively a total loss.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

28%

Total preferred funding of $28.5M represents 28.5% of estimated $100M valuation, creating a meaningful claim ahead of common.

Dilution Risk

high

No recent funding since 2021 suggests a raise is imminent; expect 20%+ dilution within 2 years.

Secondary Liquidity

none

No secondary market data available; shares are illiquid.

Business and Operations — 1 role

Science — 1 role

View all 2 open roles at Kingdom →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Kingdom's data — designed to show you've done your homework.

  • 1

    “What is the current revenue growth rate and path to profitability?”

  • 2

    “How does your licensing model compare to outright ingredient sales?”

  • 3

    “What is your vesting schedule, and has the company done a 409A valuation recently?”

Community

Valuation Sentiment

Our model estimates -57% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.